Let's complete the thought; you also agreed that (1) the fist application RECAF could get FDA approval for is in monitoring and (2) that RECAF CAN be used for monitoring since the origin of the cancer is by then known.
If these large companies find it worth taking this new cancer marker to market just for monitoring ovarian cancers (which are not very frequent compared to breast or lung cancers), the potential for RECAF - which can be used for monitoring all cancers - must be significantly bigger (or am I hyping the stock by stating the obvious...?).
RECAF should have some logistic advantages: For example, if a clinical lab can use only one test for many cancers as opposed to many tests for the same range of cancers, then the stock they need to keep in their inventory is much lower.
Gold Seeker, let us discuss for a while the potential of RECAF to monitor all types of cancer.
News 
Market Data 
Discover 
AI
